Answers are grounded in this paper and cite their sources.
// Inès Dufait 1,2 , Els Van Valckenborgh 3 , Eline Menu 3 , David Escors 4 , Mark De Ridder 1 and Karine Breckpot 2 1 Department of Radiotherapy, Vrije Universiteit, UZ-Brussel, Brussels, Belgium 2 Laboratory of Molecular and Cellular Technology, Vrije Universiteit, UZ-Brussel, Brussels, Belgium 3 Laboratory of Hematology and Immunology, Vrije Universiteit, UZ-Brussel, Brussels, Belgium 4 Immunomodulation Group, Navarrabiomed-Fundaçion, Miguel Servet, IdiSNA, Navarra, Spain Correspondence to: Karine Breckpot, email: // Keywords : MDSC, STAT3, T cell, immunotherapy, radiotherapy Received : December 17, 2015 Accepted : February 23, 2016 Published : March 23, 2016 Abstract Cancer progression is in part determined by interactions between cancer cells and stromal cells in the tumor microenvironment (TME). The identification of cytotoxic tumor-infiltrating lymphocytes has instigated research into immune stimulating cancer therapies. Although a promising direction, immunosuppressive mechanisms exerted at the TME hamper its success. Myeloid-derived suppressor cells (MDSCs) have come to the forefront as stromal cells that orchestrate the immunosuppressive TME. Consequently, this heterogeneous cell population has been the object of investigation. Studies revealed that the transcription factor signal transducer and activator of transcription 3 (STAT3) largely dictates the recruitment, activation and function of MDSCs in the TME. Therefore, this review will focus on the role of this key transcription factor during the MDSC’s life cycle and on the therapeutic opportunities it offers.
No takes yet. Share an insight, caveat, or question.
Dufait et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: